Literature DB >> 24781662

Catheter-based therapies for deep vein thrombosis.

Mahmood K Razavi1, Emmad Karmouta.   

Abstract

The basic treatment of deep vein thrombosis (DVT) over the past several decades has consisted of anticoagulation only, with inferior vena cava filtration for those who either failed or could not tolerate anticoagulation. Until recently no randomized trials had studied the efficacy of thrombolysis in DVT despite advances in techniques and technologies for endovascular clot removal. This article is a review of the current evidence on catheter-based therapies for patients with DVT. Technical considerations to improve outcome as well as optimal patient selection are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24781662     DOI: 10.1007/s11886-014-0497-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  16 in total

1.  Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis.

Authors:  Hyun S Kim; Ajanta Patra; Ben E Paxton; Jawad Khan; Michael B Streiff
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Nov-Dec       Impact factor: 2.740

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.

Authors:  M W Mewissen; G R Seabrook; M H Meissner; J Cynamon; N Labropoulos; S H Haughton
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

4.  Prevention and treatment of postphlebitic syndrome: results of a 3-part study.

Authors:  J S Ginsberg; J Hirsh; J Julian; M Vander LaandeVries; D Magier; B MacKinnon; M Gent
Journal:  Arch Intern Med       Date:  2001-09-24

5.  Endovascular management of iliac vein compression (May-Thurner) syndrome.

Authors:  G J O'Sullivan; C P Semba; C A Bittner; S T Kee; M K Razavi; D Y Sze; M D Dake
Journal:  J Vasc Interv Radiol       Date:  2000 Jul-Aug       Impact factor: 3.464

6.  Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.

Authors:  Tone Enden; Ylva Haig; Nils-Einar Kløw; Carl-Erik Slagsvold; Leiv Sandvik; Waleed Ghanima; Geir Hafsahl; Pål Andre Holme; Lars Olaf Holmen; Anne Mette Njaastad; Gunnar Sandbæk; Per Morten Sandset
Journal:  Lancet       Date:  2011-12-13       Impact factor: 79.321

7.  Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis.

Authors:  Peter H Lin; Wei Zhou; Alan Dardik; Firas Mussa; Panos Kougias; Nasim Hedayati; Joseph J Naoum; Hosam El Sayed; Eric K Peden; Tam T Huynh
Journal:  Am J Surg       Date:  2006-12       Impact factor: 2.565

8.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis.

Authors:  Ylva Haig; Tone Enden; Carl-Erik Slagsvold; Leiv Sandvik; Per Morten Sandset; Nils Einar Kløw
Journal:  J Vasc Interv Radiol       Date:  2012-11-22       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.